At the news
? MIXEDIMPACT 5/10 8-K filed Aug 6, 2026 at 07:01 ET
Immunocore reported Q2 2026 KIMMTRAK revenue of $115.9M (+18% YoY), beating consensus of $110.4M, but posted a small net loss of $0.8M ($-0.02 EPS) vs consensus expectations of $0.02 EPS. The EPS miss was driven by higher R&D spend on three Phase 3 trials. Cash position remains strong at $880M. Enrollment in the pivotal TEBE-AM trial for cutaneous melanoma is nearing completion with data possible by year-end.
- Q2 2026 KIMMTRAK net revenue $115.9M, up 18% YoY from $98.0M
- Net loss of $0.8M ($-0.02 EPS) vs net loss of $10.3M ($-0.20 EPS) in Q2 2025
- Revenue beat consensus of $110.4M; EPS missed consensus of $0.02
- Cash, cash equivalents and marketable securities $880.2M as of June 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access